Skip to content

Innovative Therapies Days 2023

Event Information:


October 12th & 13th, 2023

Besançon, France

Related Models & Services

CD34+ Humanized Mouse
Immuno-Oncology Models

Discover the Future of Cells Therapies at Innovative Therapies Days 2023 in Besançon!

Meet us at the Innovative Therapies Days on October 12th and 13th, 2023, in Besançon, France, and explore the potential of Humanized mice models in your study.

The Innovative Therapies Days will provide invaluable insights into the latest developments and breakthroughs in the field of Cells Therapies. This event boasts a comprehensive program with four sessions of conferences, exhibitions, B2B sessions, and engaging discussion forums. Renowned researchers, clinicians, and industrial partners will be sharing their expertise and knowledge, covering a wide range of topics, including CAR-T cells, pluripotent stem cells, engineered immune cells, RNA-based therapeutics, regulatory updates, and the challenges in industrial production.

Don’t miss this chance to elevate your research, expand your network, and meet TransCure bioServices! We look forward to welcoming you in Besançon!

Dan Georgess, PhD, Chief Scientific OfficerAttending in person for TransCure bioServices:

Dan Georgess, PhD, Chief Scientific Officer

Dan is an innovative scientist with extensive international experience in team leadership, research strategy, and interdisciplinary collaboration. He is dedicated to promoting cross-functional efforts to address complex challenges in therapeutics development. Prior to joining TransCure bioServices, Dan was a Marie Curie Ph.D. fellow at ENS de Lyon (France), Suzan G. Komen postdoctoral fellow at the Johns Hopkins School of Medicine (USA), and assistant professor and leader of the Cancer Invasion and Metastasis Cluster at the Lebanese American University (Lebanon). In these roles, he developed cutting-edge in vivo and ex vivo approaches for hematopoiesis, autoimmunity, and cancer research, and co-authored 15 peer-reviewed publications. Since joining TransCure bioServices in 2022, initially as Project Leader then transitioning to Director of the Alliance Management Team and now CSO, Dan’s consistent focus has been to drive successful preclinical development of cell therapies and biologics for TransCure’s clients.

This event has concluded